Personalizing cancer Immunotherapy with our DNA

Takis NeoMatrix EIT HealthCatapult HD

NEOMATRIX is a individualised therapeutic cancer vaccine against tumour specific antigens, called neoantigens, arising from somatic gene mutations in malignant cells during neoplastic transformation. The tailored vaccine is intended for use as therapeutic vaccination in patients with locally advanced or metastatic solid tumours.

The process

Tumor Biopsies are taken from patient

RNA and DNA are sequenced by Next Generation Sequences

100-150mg DNA plasmids are manufactured in GMP conditions

The entire process is predicted to be back to the patient in 6 weeks

Tumor Biopsies are taken from patient

RNA and DNA are sequenced by Next Generation Sequences

Neoantigens are identified through a pipeline called NARciso

Codon Optimized Vaccine is synthesized in Takis Laboratories

100-150mg DNA plasmids are manufactured in GMP conditions

The entire process is predicted to be back to the patient in 6 weeks

The process

To learn how NeoMatrix works click here

To learn how NeoMatrix works click here

Where we are

Preclinical studies completed

Biomarker assay under advanced development

Specialty Oncology Centers / KOLs identified and ready to start

Cancer Targets

Melanoma

Lung Cancer

Brands and Partners

Our Partners

Takis

Evvivax

Vitares

Reference

The perfect personalized cancer therapy: cancer vaccines against neoantigens.

Aurisicchio L, Pallocca M, Ciliberto G, Palombo F.
J Exp Clin Cancer Res. 2018 Apr 20;37(1):86. doi: 10.1186/s13046-018-0751-1

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874958

Luigi Aurisicchio, CEO
Neomatrix biotech - Rome, Italy

Fabio Palombo, CSO
Neomatrix biotech - Rome, Italy

© 2023 NEOMATRIX SRL | P. IVA 15698291000 | ALL RIGHTS RESERVED